Table 2 miRNA target genes KEGG pathway enrichment
CRBLM | CRBLM | CRBLM | FCTX | FCTX | PONS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
vs | vs | vs | vs | vs | vs | ||||||||
FCTX | PONS | TCTX | PONS | TCTX | TCTX | ||||||||
KEGG pathways | R | N | R | N | R | N | R | N | R | N | R | N | |
1 | TGF- β signaling pathway | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
2 | Glioma ∗ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
3 | MAPK signaling pathway | ○ | ○ | ○ | ○ | ○ | |||||||
4 | Axon guidance ∗ | ○ | ○ | ○ | ○ | ||||||||
5 | Phosphatidylinositol signaling system | ○ | ○ | ○ | |||||||||
6 | mTOR signaling pathway | ○ | ○ | ○ | |||||||||
7 | Adipocytokine signaling pathway | ○ | ○ | ○ | ○ | ||||||||
8 | Pancreatic cancer | ○ | ○ | ○ | ○ | ||||||||
9 | Endocytosis | ○ | ○ | ○ | ○ | ○ | |||||||
10 | Focal adhesion | ○ | ○ | ○ | ○ | ○ | |||||||
11 | Insulin signaling pathway | ○ | ○ | ○ | ○ | ||||||||
12 | Neurotrophin signaling pathway ∗ | ○ | ○ | ○ | ○ | ||||||||
13 | Colorectal cancer | ○ | ○ | ○ | ○ | ||||||||
14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ○ | ○ | ○ | ○ | ○ | |||||||
15 | Wnt signaling pathway | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
16 | Non-small cell lung cancer | ○ | ○ | ||||||||||
17 | Adherens junction | ○ | ○ | ○ | ○ | ○ | |||||||
18 | ErbB signaling pathway | ○ | ○ | ○ | ○ | ||||||||
19 | Pathways in cancer | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
20 | Glycosaminoglycan biosynthesis - heparan sulfate | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
21 | Type II diabetes mellitus | ○ | ○ | ||||||||||
22 | Melanoma | ○ | ○ | ○ | ○ | ||||||||
23 | Renal cell carcinoma | ○ | ○ | ○ | ○ | ||||||||
24 | Inositol phosphate metabolism | ○ | ○ | ||||||||||
25 | Chronic myeloid leukemia | ○ | ○ | ○ | ○ | ○ | |||||||
26 | T cell receptor signaling pathway | ○ | ○ | ||||||||||
27 | Small cell lung cancer | ○ | ○ | ○ | |||||||||
28 | Fc gamma R-mediated phagocytosis | ○ | ○ | ○ | |||||||||
29 | Prostate cancer | ○ | ○ | ○ | |||||||||
30 | Salivary secretion | ○ | ○ | ||||||||||
31 | Osteoclast differentiation | ○ | ○ | ||||||||||
32 | Regulation of actin cytoskeleton | ○ | ○ | ○ | ○ | ||||||||
33 | Endocrine and other factor-regulated calcium reabsorption | ○ | ○ | ||||||||||
34 | Lysine degradation | ○ | ○ | ○ | |||||||||
35 | Circadian rhythm - mammal | ○ | ○ | ○ | ○ | ||||||||
36 | Glycosaminoglycan biosynthesis - chondroitin sulfate | ○ | ○ | ○ | |||||||||
37 | N-Glycan biosynthesis | ○ | ○ | ||||||||||
38 | Long-term depression | ○ | ○ | ||||||||||
39 | Prion diseases | ○ | ○ | ||||||||||
40 | ECM-receptor interaction | ○ | ○ | ||||||||||
41 | Tight junction | ○ | ○ | ||||||||||
42 | Hypertrophic cardiomyopathy (HCM) | ○ | ○ | ||||||||||
43 | Cell adhesion molecules (CAMs) | ○ | ○ | ||||||||||
44 | Dilated cardiomyopathy | ○ | ○ | ||||||||||
45 | Fatty acid biosynthesis | ○ | |||||||||||
46 | Long-term potentation | ○ | |||||||||||
47 | Ubiquitin mediated proteolysis | ○ | |||||||||||
48 | Thyroid cancer | ○ | |||||||||||
49 | Notch signaling pathway | ○ | |||||||||||
50 | Mismatch repair | ○ | |||||||||||
51 | Acute myeloid leukemia | ○ | |||||||||||
52 | Glycosphingolipid biosynthesis - lacto and neolacto series | ○ | |||||||||||
53 | Glycosaminoglycan biosynthesis - keratan sulfate | ○ | |||||||||||
54 | Biotin metabolism | ○ | |||||||||||
55 | Gap junction | ○ | |||||||||||
56 | Gastric acid secretion | ○ | |||||||||||
57 | Taurine and hypotaurine metabolism | ○ | |||||||||||
58 | Aldosterone-regulated sodium reabsorption | ○ | |||||||||||
59 | GnRH signaling pathway | ○ | |||||||||||
60 | Metabolism of xenobiotics by cytochrome P450 | ○ | |||||||||||
61 | Mucin type O-Glycan biosynthesis | ○ | |||||||||||
62 | Biosynthesis of unsaturated fatty acids | ○ | |||||||||||
63 | Viral myocarditis | ○ | |||||||||||
64 | Cytokine-cytokine receptor interaction | ○ | |||||||||||
65 | Hematopoietic cell lineage | ○ | |||||||||||
66 | Valine, leucine and isoleucine biosynthesis | ○ | |||||||||||